Arcellx (ACLX) Shares Encouraging Data on Latest Lab Study
Arcellx Incorporated (NASDAQ:ACLX) is one of 17 Biotech Stocks With More Than 50% Up. On February 12, Qize Ding of Rothschild & Co Redburn downgraded Arcellx Incorporated (NASDAQ:ACLX) from Buy to Neutral. In the process, it also lowered the price target from $113 to $82, still yielding a revised upside potential of nearly 20%. Ding’s…